Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,585 signal articles · 328 in last 24h · 112,405 total before filter · latest 43m ago
328last 24h
2140last 7d
379● bullish (7d)
188● bearish (7d)
204publishers
AllMacro296Earnings1216M&A90Regulatory23Product13Analyst20
✕ clear all filtersticker: NOVTSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Novanta (NOVT) Lifted Guidance And Closed Riverpoint, Is The Upside Already Priced In?
Simply Wall St.4d agoneutral
Novanta (NOVT) Lifted Guidance And Closed Riverpoint, Is The Upside Already Priced In?

What Novanta’s latest guidance and Q2 results mean for the stock Novanta (NOVT) put fresh numbers on the table on 5 August 2026, pairing new third quarter and full year revenue guidance with second quarter results and the recently closed Riverpoint Medical acquisition. The company now guides third quarter 2026 GAAP revenue to US$300 million to US$304 million, with the range reflecting an expected contribution from Riverpoint Medical and an assumption of steady foreign exchange rates. For full...

Novanta Q2 Earnings Call Highlights
MarketBeat6d agoneutral
Novanta Q2 Earnings Call Highlights

Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa

The Bull Case For Novanta (NOVT) Could Change Following An Earnings-Driven Analyst Upgrade - Learn Why
Simply Wall St.46d agobullish
The Bull Case For Novanta (NOVT) Could Change Following An Earnings-Driven Analyst Upgrade - Learn Why

Novanta was recently upgraded to a Zacks Rank #2 (Buy), reflecting increased analyst optimism tied to an upward revision in earnings estimates. This earnings-driven upgrade highlights how changing expectations about Novanta's profit outlook can influence investor attention and perceived business strength over time. Next, we'll examine how the upgraded earnings outlook and analyst ranking could reshape Novanta's existing investment narrative and risk profile. Invest in the nuclear...

Novanta’s Q1 Earnings Call: Our Top 5 Analyst Questions
StockStory85d agoneutral
Novanta’s Q1 Earnings Call: Our Top 5 Analyst Questions

Novanta’s first quarter saw a strong positive market reaction, reflecting confidence in management’s execution and commercial momentum. The company credited broad-based demand and robust bookings, particularly in the Robotics & Automation and Advanced Surgery businesses, as central to its performance. CEO Matthijs Glastra highlighted that every segment achieved double-digit bookings growth, with new product revenue rising sharply. Management specifically pointed to ongoing strength in medical co

Novanta (NOVT) Q1 2026 Earnings Transcript
Motley Fool92d agoneutral
Novanta (NOVT) Q1 2026 Earnings Transcript

This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night and also those in our SEC filings.

Novanta (NOVT) Valuation Check After Earnings Beat And Strong Guidance Shift
Simply Wall St.92d agobullish
Novanta (NOVT) Valuation Check After Earnings Beat And Strong Guidance Shift

Novanta (NOVT) just posted first quarter results that beat earnings and revenue expectations, with sales of US$257.71 million and forward guidance above analyst estimates, marking a shift after earlier quarters of missed forecasts. See our latest analysis for Novanta. The strong first quarter beat and improved guidance appear to be feeding into momentum, with the share price up 11.8% over the past month and a year to date share price return of 26%. This is despite the 3 year total shareholder...

Novanta Q1 Earnings Call Highlights
MarketBeat92d agoneutral
Novanta Q1 Earnings Call Highlights

Novanta (NASDAQ:NOVT) reported stronger-than-expected first-quarter 2026 results, with management citing broad-based bookings growth, accelerating demand in automation and medical markets, and rising exposure to artificial intelligence-related infrastructure applications. Chair and Chief Executive